TD Cowen Bullish on Ideaya's (IDYA) Oncology Pipeline

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 22, TD Cowen began coverage of IDYA with a Buy rating, highlighting the company’s $1.91 billion valuation and strong analyst consensus. A doctor delivering the results of an epigenetics-based clinical test to a patient. Price targets span $25 to $66, reflecting optimism for its expanding pipeline, which is set to include nine clinical-stage programs that the firm praised as “the best of targeted oncology.” Among the highlights, TD Cowen emphasized the daro + criz combo therapy targeting metastatic uveal melanoma, with a 2026 launch and promising neoadjuvant prospects. The firm also signaled confidence in upcoming DLL3 ADC results and noted that MAT2A’s efficacy could complement Trodelvy treatments, adding further depth to Ideaya’s clinical momentum. IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a clinical-stage oncology company focused on discovering and developing targeted therapies for cancer patients. It utilizes molecular diagnostics to identify patient populations most likely to benefit from their therapies. While we acknowledge the potential of IDYA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Airline Stocks to Buy According to Hedge Funds and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey.